Zacks has a buy on small cap Osiris and gives the company a $20 price target. This company makes drugs from human stems cells. In a partnership with Genzyme, they were recently awarded a $225 million contract from the Department of Defense.
Another article on the company was found at Seeking Alpha.
No comments:
Post a Comment